

Smita K Nair

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/966222/publications.pdf>

Version: 2024-02-01

85
papers

5,980
citations

109321

35
h-index

74163

75
g-index

88
all docs

88
docs citations

88
times ranked

7008
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	27.0	570
2	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
3	Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. <i>Nature Biotechnology</i> , 1998, 16, 364-369.	17.5	383
4	Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. <i>Nature Medicine</i> , 2000, 6, 1011-1017.	30.7	350
5	Immunotherapy of cancer with dendritic-cell-based vaccines. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 82-87.	4.2	277
6	From the RNA world to the clinic. <i>Science</i> , 2016, 352, 1417-1420.	12.6	225
7	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017, 23, 1898-1909.	7.0	215
8	Paracrine Wnt5a- β -Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. <i>Immunity</i> , 2018, 48, 147-160.e7.	14.3	185
9	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	180
10	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. <i>International Journal of Cancer</i> , 1997, 70, 706-718.	5.1	178
11	Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells. <i>Annals of Surgery</i> , 2002, 235, 540-549.	4.2	177
12	RNA-Based Vaccines in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	2.2	169
13	Synergy between tumor immunotherapy and antiangiogenic therapy. <i>Blood</i> , 2003, 102, 964-971.	1.4	162
14	Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation. <i>Journal of Immunology</i> , 2003, 171, 6275-6282.	0.8	160
15	Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responses in vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea. <i>International Journal of Cancer</i> , 1999, 82, 121-124.	5.1	151
16	Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. <i>Cancer Research</i> , 2003, 63, 7483-9.	0.9	148
17	Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity. <i>Cancer Research</i> , 2007, 67, 371-380.	0.9	140
18	Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. <i>Journal of Controlled Release</i> , 2013, 166, 227-233.	9.9	123

#	ARTICLE	IF	CITATIONS
19	Isolation and Generation of Human Dendritic Cells. <i>Current Protocols in Immunology</i> , 2012, 99, Unit7.32.	3.6	100
20	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. <i>Scientific Reports</i> , 2014, 4, 5128.	3.3	94
21	Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. <i>European Journal of Immunology</i> , 1997, 27, 589-597.	2.9	86
22	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018, 78, 256-264.	0.9	82
23	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
24	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 2684-2694.	7.0	74
25	Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. <i>European Journal of Immunology</i> , 1998, 28, 1923-1933.	2.9	69
26	Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. <i>European Journal of Immunology</i> , 2011, 41, 3553-3563.	2.9	67
27	Induction of Human Dendritic Cell Maturation Using Transfection with RNA Encoding a Dominant Positive Toll-Like Receptor 4. <i>Journal of Immunology</i> , 2004, 172, 7162-7168.	0.8	63
28	Messenger RNA (mRNA) nanoparticle tumour vaccination. <i>Nanoscale</i> , 2014, 6, 7715-7729.	5.6	63
29	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. <i>Journal of Clinical Investigation</i> , 2013, 123, 3135-3145.	8.2	55
30	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. <i>Oncotarget</i> , 2016, 7, 79828-79841.	1.8	53
31	Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity. <i>Journal of Controlled Release</i> , 2018, 269, 364-373.	9.9	52
32	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. <i>Nature Communications</i> , 2021, 12, 1858.	12.8	47
33	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 774-788.	8.2	47
34	Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	4.8	44
35	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. , 2021, 9, e002203.		44
36	Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. <i>Science Advances</i> , 2021, 7, .	10.3	42

#	ARTICLE	IF	CITATIONS
37	Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?. <i>Cancer Research</i> , 2019, 79, 2447-2456.	0.9	41
38	Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing <i>in vitro</i> antigen-specific T cell responses. <i>Immunology</i> , 2008, 125, 229-240.	4.4	38
39	Whole Blood Cells Loaded with Messenger RNA as an Anti-Tumor Vaccine. <i>Advanced Healthcare Materials</i> , 2014, 3, 837-842.	7.6	34
40	DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. <i>Biomaterials</i> , 2022, 283, 121393.	11.4	34
41	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
42	Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during <i>in vitro</i> costimulation assay using specific antigens. <i>Journal of Leukocyte Biology</i> , 1995, 57, 310-316.	3.3	29
43	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. <i>Nature Communications</i> , 2020, 11, 524.	12.8	29
44	Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. <i>Cancer Cell</i> , 2022, 40, 439-440.	16.8	27
45	Programming Human Dendritic Cells with mRNA. <i>Methods in Molecular Biology</i> , 2013, 969, 111-125.	0.9	25
46	Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. <i>Clinical Breast Cancer</i> , 2018, 18, 410-417.	2.4	24
47	Immunological targeting of cytomegalovirus for glioblastoma therapy. <i>Oncolmmunology</i> , 2014, 3, e29289.	4.6	23
48	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 65-74.	2.9	22
49	RNA-transfected dendritic cells. <i>Expert Review of Vaccines</i> , 2002, 1, 507-513.	4.4	20
50	Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart. <i>Advanced Science</i> , 2022, 9, e2103672.	11.2	20
51	RNA as performance-enhancers for dendritic cells. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 563-574.	3.1	19
52	Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. <i>Molecular Therapy</i> , 2021, 29, 1772-1781.	8.2	18
53	Immunologic Targeting of FOXP3 in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e53150.	2.5	16
54	Intratumoral delivery of brachytherapy and immunotherapy by a thermally triggered polypeptide depot. <i>Journal of Controlled Release</i> , 2022, 343, 267-276.	9.9	15

#	ARTICLE	IF	CITATIONS
55	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3501-3510.	1.5	13
56	Oncolytic viruses in melanoma. <i>Frontiers in Bioscience</i> , 2022, 27, 063.	2.1	12
57	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	5.1	11
58	A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neopeptide. <i>Npj Vaccines</i> , 2021, 6, 12.	6.0	8
59	Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. <i>Nanophotonics</i> , 2021, 10, 3295-3302.	6.0	8
60	Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2022, 137, 67-78.	2.5	8
61	High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted <i>Mycobacterium tuberculosis</i> epitopes. <i>Scientific Reports</i> , 2014, 4, 4632.	3.3	7
62	RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit ⁺ Cardiac Progenitor Cells. <i>Stem Cells and Development</i> , 2015, 24, 2622-2633.	2.1	7
63	RNA Vaccination Therapy: Advances in an Emerging Field. <i>Journal of Immunology Research</i> , 2016, 2016, 1-2.	2.2	6
64	Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 475-483.	4.2	6
65	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019, 21, vi7-vi7.	1.2	5
66	Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12641-e12641.	1.6	5
67	β ² -Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes. <i>Molecular Therapy</i> , 2022, 30, 845-854.	8.2	5
68	The <i>In Vitro</i> Differentiation of Human CD141 ⁺ CLEC9A ⁺ Dendritic Cells from Mobilized Peripheral Blood CD34 ⁺ Hematopoietic Stem Cells. <i>Current Protocols</i> , 2022, 2, e410.	2.9	5
69	Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2005-2005.	1.6	5
70	Engineering B Cells with mRNA. <i>Methods in Molecular Biology</i> , 2013, 969, 101-110.	0.9	3
71	Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. <i>Journal of Controlled Release</i> , 2015, 213, e66-e67.	9.9	2
72	Transfecting Human Monocytes with RNA. <i>Methods in Molecular Biology</i> , 2016, 1428, 177-186.	0.9	2

#	ARTICLE	IF	CITATIONS
73	Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. , 1997, 70, 706.		2
74	Immune profiling of BRCA-mutated breast cancers.. Journal of Clinical Oncology, 2018, 36, 585-585.	1.6	2
75	The RNAissance period. Discovery Medicine, 2016, 22, 67-72.	0.5	2
76	Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. Methods in Molecular Biology, 2022, 2410, 609-626.	0.9	2
77	Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-10.	2.2	1
78	IMMU-31. DYSFUNCTIONAL STING PATHWAY SIGNALING COMPROMISES INNATE IMMUNITY IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi127-vi128.	1.2	1
79	Key Pathogenic Factors in Coronavirus Disease 2019â€™Associated Coagulopathy and Acute Lung Injury Highlighted in a Patient With Copresentation of Acute Myelocytic Leukemia: A Case Report. A&A Practice, 2021, 15, e01432.	0.4	1
80	Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.. Journal of Clinical Oncology, 2021, 39, 2561-2561.	1.6	1
81	A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.. Journal of Clinical Oncology, 2017, 35, 102-102.	1.6	1
82	Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.. Journal of Clinical Oncology, 2016, 34, 602-602.	1.6	0
83	Understanding the peripheral cellular immunome in patients with breast cancer.. Journal of Clinical Oncology, 2019, 37, 7-7.	1.6	0
84	Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 273-273.	1.6	0
85	Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs).. Journal of Clinical Oncology, 2020, 38, e13096-e13096.	1.6	0